Related Experiment Video

Updated: Oct 23, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

370

The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative

Nonthaphat Kent Wong1, Shumeng Luo1, Eudora Y D Chow2

  • 1Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.

Frontiers in Cell and Developmental Biology
|August 20, 2021
PubMed

Insights

This study identifies a novel long non-coding RNA (lncRNA), LNC000093, that plays a crucial role in drug resistance and the tumor microenvironment of myeloproliferative neoplasms (MPNs), offering new therapeutic targets.

Area of Science:

  • * Molecular Biology
  • * Oncology
  • * Genetics

Background:

  • * Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cellular processes, including cancer development.
  • * The specific functions of many lncRNAs, particularly in myeloproliferative neoplasms (MPNs), remain largely uncharacterized.
  • * Understanding lncRNA mechanisms is crucial for developing novel therapeutic strategies against MPNs.

Purpose of the Study:

  • * To investigate the role of novel lncRNAs and microRNAs (miRNAs) in modulating drug response and the tumor microenvironment in MPNs.
  • * To identify specific lncRNAs involved in tyrosine kinase inhibitor (TKI) resistance in chronic myelogenous leukemia (CML).
  • * To elucidate the functional mechanisms of identified lncRNAs in MPN pathogenesis.

Main Methods:

  • * mRNA sequencing was employed to identify novel lncRNAs in TKI-treated leukemic cell lines from MPN patients.
  • * Expression levels of LNC000093 were validated in patient-derived cells and tissues.
  • * Molecular mechanisms, including competitive endogenous RNA (ceRNA) activity and exosomal transfer, were investigated.

Main Results:

  • * A novel lncRNA, LNC000093, was identified and its expression inversely correlated with TKI resistance in CML.
  • * LNC000093 acts as a ceRNA for miR-675-5p, reversing imatinib resistance by regulating RUNX1.
  • * LNC000093 influences the tumor microenvironment via exosomal H19/miR-675, affecting VEGF expression.

Conclusions:

  • * The novel lncRNA LNC000093 is a key regulator of drug response and tumor microenvironment modulation in MPNs.
  • * LNC000093 represents a potential therapeutic target for overcoming TKI resistance in CML.
  • * Further research into lncRNA-miRNA interactions offers promising avenues for MPN treatment.
Keywords:
chronic myelogenous leukemialong non-coding RNAsmolecular targetsmyeloproliferative neoplasmstyrosine kinase inhibitor

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.3K